Synthesis, structural characterization and biological activity of 2-(4-methylbenzenesulphonamido)pentanedioic acid amide derivatives: In vitro and in vivo antineoplastic activity
In the present work few novel 2-(4-methylbenzenesulphonamido)pentanedioic acid amide derivatives and the basic compound 2-(4-methylphenylsulfonamido)pentanedioic acid have been synthesized, characterized and screened for their possible antineoplastic activity both in vitro and in vivo. The in vitro activity was performed against five human cell lines like human breast cancer (MCF-7), leukemia (K-562), ovarian cancer (OVACAR-3), human colon adenocarcinoma (HT-29) and Human kidney carcinoma (A-498). The in vivo activity was performed in female swiss albino mice against Ehrlich ascites carcinoma (EAC). Among the synthesized compounds, ureide, p-bromoanilide, p-nitoanilide, o-bromoanilide and p-methylanilide derivatives of 2-(4-methyl benzene sulphonyl)-pentanedioic acid amides showed encouraging activity in both the in vitro and in vivo compared to other compounds. It was noticed that final derivative compounds show a better activity than the parent compound and it may be due to the substituents present in those compounds.
Dantu AS, Shankarguru P, Ramya D D, Vedha HBN. Evaluation of in vitro anticancer activity of hydroalcoholic extract of Tabernaemontana divaricata. Asian J Pharmaceut Clin Res. 2012; 5: 59-61.
De AU, Pal D. Possible antineoplastic agents I. J Pharm Sci. 1975; 64: 262-66.
De AU, Pal D. Possible antineoplastic agents II. J Pharm Sci. 1977; 66: 232-35.
Debnath B, Srikanth K, Banerjee S, Jha T. 1,5-N,N´-Disubstituted-2-(substituted benzenesulphonyl)-glutamamides as antitumor agents. Part 2. Synthesis, biological activity and QSAR study. Internet Electron J Mol Des. 2002; 1: 488-502.
Eckhardt AE, Malone BN, Goldstein IJ. Inhibition of Ehrlich ascites tumor cell growth by Griffonia simplicifolia I Lectin in vivo. Cancer Res. 1982; 42: 2977-79.
Eidinoff ML. Pyrimidine studies: I. Effect of DON (6-Diazo-5-oxo-L-norleucine) on incorporation of precursors into nucleic acid pyrimidines. Cancer Res. 1958; 18: 105-09.
Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, Fattotossi A, Isola G, Benedetti Panici P, Mancuso S. Tamoxifen induces oxidative stress and apotosis in oestrogen receptor-negative human cancer cell line. Br J Cancer. 1999; 79: 257-63.
Gelman EP. Tamoxifen for the treatment of malignancies other breast and endometrial carcinoma. Semin Oncol. 1997; Suppl 1.24: 165-70.
Graff S, Rittenberg D and Foster GL. The glutamic acid of malignant tumors. J Biol Chem. 1940; 133: 745-52.
Hartman SC. Metabolic pathways. New York, Academic Press, 1970, pp 1-5.
Holbeck SL. Update on NCI in vitro drug screen utilities. Eur J Cancer. 2004; 40: 785-93.
Keren R, Stark AA. Gamma-glutamyl transpeptidase-dependent mutagenicity and cytotoxicity of gamma-glutamyl derivatives: A model for biochemical targeting of chemotherapeutic agents. Environ Mol Mutagen. 1998; 32: 377-86.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63.
NCI. PDQ Clinical trial Search Bethesda. USA, National Cancer Institute, 1999.
Petit GR. Biosynthetic products for cancer chemotherapy. New York, Plenum Press, 1977. pp 158-62.
Ray S, De AU. Synthesis and biological activity of succinimidobenzenesulfonyl oxopyrrolidine analogs as possible antineoplastic agent. Asian J Chem. 2009; 21: 379-87.
Rodwell VW. Metabolism of purine and pyrimidine nucleotides. 25th ed. Stamford, Connecticut, Appleton and Lange, 2000, pp 386-92.
Rosowsky A, Wick MM, Kin SH. Structural analogs of L-glutamic acid-(4-hydroxyanalide) and -(3,4-dihydroxyanalide) as potential agents against melanoma. J Med Chem. 1979; 22: 1034-37.
Sugita Y. The effect of Antineoplaston, a new antitumor agent on malignant brain tumors. Kurume Med J. 1995; 42: 133-40.
Copyright (c) 2015 Satyajit Dutta, G. Raghava Ravali, Supratim Ray, K. Nagarajan
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).